American Journal of Ophthalmology最新文献

{"title":"Comment on “Inner Choroidal Fibrosis: An Optical Coherence Tomography Biomarker of Severity in Chronic Central Serous Chorioretinopathy”","authors":"Felipe de Queiroz Tavares Ferreira","doi":"10.1016/j.ajo.2024.04.033","DOIUrl":"10.1016/j.ajo.2024.04.033","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"269 ","pages":"Pages 502-503"},"PeriodicalIF":4.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Comment on: Inner Choroidal Fibrosis: An Optical Coherence Tomography Biomarker of Severity in Chronic Central Serous Chorioretinopathy","authors":"Saarang Hansraj , Jay Chhablani , Umesh Chandra Behera , Ritesh Narula , Raja Narayanan , Niroj Kumar Sahoo","doi":"10.1016/j.ajo.2024.05.016","DOIUrl":"10.1016/j.ajo.2024.05.016","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"269 ","pages":"Pages 504-505"},"PeriodicalIF":4.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Comment on Subgroup Analysis From a Phase 1/2 Randomized Clinical Trial of 2.6% EDTA Ophthalmic Solution in Patients With Age-Related Cataract","authors":"TATSUYA KUBOI , ROY S. CHUCK , ROBERTO PINEDA II , RAJIV BHUSHAN , AMIT GOSWAMY , RANDALL J. OLSON","doi":"10.1016/j.ajo.2024.09.016","DOIUrl":"10.1016/j.ajo.2024.09.016","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"269 ","pages":"Page 498"},"PeriodicalIF":4.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142306852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Long-Term Postoperative Outcomes Following Cionni Ring and In-the-Bag Intraocular Lens Implantation in Eyes with Subluxated Lenses","authors":"MUHAMMED SAGDIC , FIKRET UCAR","doi":"10.1016/j.ajo.2024.08.046","DOIUrl":"10.1016/j.ajo.2024.08.046","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"269 ","pages":"Pages 499-500"},"PeriodicalIF":4.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Comment on: Long-term postoperative outcomes following Cionni ring and in-the-bag intraocular lens implantation in eyes with subluxated lenses","authors":"Rasikpriya Sandhu, Vijayvarschini Shankar, Vaishali Vasavada, Shail Vasavada, Abhay R. Vasavada, Viraj A. Vasavada","doi":"10.1016/j.ajo.2024.09.032","DOIUrl":"10.1016/j.ajo.2024.09.032","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"269 ","pages":"Page 501"},"PeriodicalIF":4.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Practice Patterns and Sociodemographic Disparities in the Clinical Care of Anatomical Narrow Angles in the United States\" [American Journal of Ophthalmology Volume 261 (2024) Pages 66-75].","authors":"Kristy Yoo, Galo Apolo, Khristina Lung, Brian Toy, Benjamin Xu","doi":"10.1016/j.ajo.2024.12.008","DOIUrl":"https://doi.org/10.1016/j.ajo.2024.12.008","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perivascular Chorioretinal Atrophy: An Unusual Feature in Pathologic Myopia Eyes","authors":"Romain Benahmed ,&nbsp;Lea Dormegny ,&nbsp;Alain Gaudric ,&nbsp;Elise Philippakis ,&nbsp;Arnaud Sauer ,&nbsp;Tristan Bourcier ,&nbsp;Aude Couturier ,&nbsp;David Gaucher","doi":"10.1016/j.ajo.2024.12.022","DOIUrl":"10.1016/j.ajo.2024.12.022","url":null,"abstract":"<div><h3>PURPOSE</h3><div>To describe a largely unrecognized feature in pathologic myopia, namely, perivascular patchy chorioretinal atrophy (PVCA).</div></div><div><h3>DESIGN</h3><div>Cross-sectional study.</div></div><div><h3>METHODS</h3><div>A total of 604 eyes of 312 highly myopic patients followed at Strasbourg University Hospitals were reviewed for the presence of PVCA lesions. Demographic, clinical, and paraclinical data (ultra-widefield retinography, optical coherence tomography [OCT], fluorescein and indocyanine green angiography images) were analyzed. Controls were matched for age, sex, and axial length (AL).</div></div><div><h3>RESULTS</h3><div>A total of 47 eyes (7.8%) of 32 patients presented with 88 PVCA lesions in total. Mean age was 65.9 ± 10.2 years, and mean best corrected visual acuity (BVCA) was 0.86 ± 0.76 logMAR. All patients had posterior staphyloma, with PVCA localized within the staphyloma (58%), on its margins (39%), or outside of it (3%). Atrophic lesions were mainly located in the temporal retina (71%) and on the first- or second-order branches of the central retinal vessels (95%). OCT scans revealed an anterior scleral protrusion in 74% of cases, with an average height of 319 ± 152 µm. PVCA patients had longer AL (32.94 ± 1.87 mm vs 29.96 ± 2.79 mm; <em>P</em> &lt; .01) than non-PVCA patients. When compared to matched controls, PVCA patients had lower BCVA (0.86 ± 0.76 logMAR vs 0.59 ± 0.71 logMAR; <em>P</em> = .01) and reduced macular choroidal thickness (38 ± 31 µm vs 54 ± 38 µm; <em>P</em> = .02).</div></div><div><h3>CONCLUSION</h3><div>PVCA is a newly described feature of pathological myopia associated with reduced visual acuity. Its association with anterior scleral protrusion suggests that scleral curvature change may represent a specific cause leading to chorioretinal atrophy.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"271 ","pages":"Pages 498-506"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Renal Adverse Events Between Intravitreal Anti–Vascular Endothelial Growth Factor Agents: A Meta-Analysis","authors":"Ryan S. Huang ,&nbsp;Michael Balas ,&nbsp;Aaditeya Jhaveri ,&nbsp;Marko M. Popovic ,&nbsp;Peter J. Kertes ,&nbsp;Rajeev H. Muni","doi":"10.1016/j.ajo.2024.12.023","DOIUrl":"10.1016/j.ajo.2024.12.023","url":null,"abstract":"<div><h3>PURPOSE</h3><div>To compare the risk of renal adverse events, particularly acute kidney injury (AKI), between intravitreal anti–vascular endothelial growth factor (anti-VEGF) agents.</div></div><div><h3>DESIGN</h3><div>Meta-analysis.</div></div><div><h3>METHODS</h3><div>A systematic literature search was conducted on Ovid Medline, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published from January 2005 to February 2024 involving adult patients receiving anti-VEGF intravitreal injections for age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion. The primary outcome was the comparative risk of AKI between anti-VEGF agents and sham injections. Secondary outcomes involved other renal adverse events. Subgroup analyses were conducted by specific disease indications. A random-effects model was used for meta-analysis to estimate risk ratios (RRs) and their 95% confidence intervals, with a <em>P</em> value of &lt;.05 representing statistical significance. Risk of bias was assessed using the Cochrane Risk of Bias 2 (ROB2) tool, and the certainty of evidence was evaluated through the Cochrane Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework.</div></div><div><h3>RESULTS</h3><div>A total of 10,031 eyes from 11 RCTs were included. No significant differences were found in the risk of acute or chronic renal conditions, obstructive uropathies, neoplasia, or infectious processes between anti-VEGF agents and sham therapy. AKI was reported in 5.4% (n = 10/185) of patients treated with bevacizumab, 1.3% (n = 6/456) with sham, 1.0% (n = 48/4724) with aflibercept, 0.8% (n = 15/1929) with faricimab, 0.5% (n = 5/1098) with brolucizumab, and 0.3% (n = 5/1639) with ranibizumab. No significant differences in AKI risk were observed between any of the anti-VEGF agents and sham (<em>P</em> &gt; .05 for all comparisons). However, there was an increased risk of patient-reported symptoms with 1.25 mg bevacizumab compared to 2 mg aflibercept (RR = 3.26, 95% CI = 1.07-9.93, <em>P</em> = .04), driven primarily by reports of hematuria: 4.3% (bevacizumab), 0.7% (sham), 0.2% (aflibercept), 0.1% (faricimab), and 0.1% (ranibizumab).</div></div><div><h3>CONCLUSIONS</h3><div>US Food and Drug Administration (FDA)–approved intravitreal anti-VEGF agents do not significantly increase the risk of AKI compared to sham injections. Nevertheless, variations in patient-reported renal symptoms were observed across different anti-VEGF drugs. These variations were influenced primarily by differences in hematuria events, which may be a result of differential systemic absorption by these agents. These results underscore the importance of continuous monitoring and pharmacovigilance.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"271 ","pages":"Pages 466-477"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ophthalmology Journals’ Guidelines on Generative Artificial Intelligence: A Comprehensive Analysis","authors":"Wenqiao Huang ,&nbsp;Yating Liang ,&nbsp;Xianghui Wei ,&nbsp;Yi Du","doi":"10.1016/j.ajo.2024.12.021","DOIUrl":"10.1016/j.ajo.2024.12.021","url":null,"abstract":"<div><h3>Purpose</h3><div>The integration of generative artificial intelligence (GAI) into scientific research and academic writing has generated considerable controversy. Currently, standards for using GAI in academic medicine remain undefined. This study aims to conduct a comprehensive analysis of the guidance provided for authors regarding the use of GAI in ophthalmology scientific journals.</div></div><div><h3>Design</h3><div>Cross-sectional bibliometric analysis.</div></div><div><h3>Participants</h3><div>A total of 140 ophthalmology journals listed in the Scimago Journal and Country Rankings, regardless of language or origin.</div></div><div><h3>Methods</h3><div>We systematically searched and screened the 140 ophthalmology journals’ websites on October 19 and 20, 2024, and conducted updates on November 19 and 20, 2024.</div></div><div><h3>Main Outcome Measures</h3><div>The content of GAI guidelines from the websites of the 140 ophthalmology journals.</div></div><div><h3>Results</h3><div>Of 140 journals reviewed, 96 (69%) provide explicit guidelines for authors regarding the use of GAI. Among these, nearly all journals agree on 3 key points: (1) 94 journals (98%) have established specific guidelines prohibiting GAI from being listed as an author; (2) 94 journals (98%) emphasize that human authors are responsible for the outputs generated by GAI tools; and (3) all 96 journals require authors to disclose any use of GAI. In addition, 20 journals (21%) specify that their guidelines pertain solely to the writing process with GAI. Furthermore, 92 journals (66%) have developed guidelines concerning GAI-generated images, with 63 journals (68%) permitting their use and 29 (32%) prohibiting them. Among those that prohibit GAI images, 27 journals (93%) allow their use under specific conditions.</div></div><div><h3>Conclusion</h3><div>Although there is considerable ethical consensus among ophthalmology journals regarding the use of GAI, notable variations exist in terms of permissible use and disclosure practices. Establishing standardized guidelines is essential to safeguard the originality and integrity of scientific research. Researchers must uphold high standards of academic ethics and integrity when using GAI.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"271 ","pages":"Pages 445-454"},"PeriodicalIF":4.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing the Effect of Surgical and Corneal Parameters on the Postoperative Refractive Outcomes of Smile in Myopic Eyes Based on Machine Learning","authors":"MINGDONG ZHANG ,&nbsp;SHUFAN JI ,&nbsp;YAN HUO ,&nbsp;SHAOHU BAI ,&nbsp;ZIHENG TAO ,&nbsp;JIAMEI ZHANG ,&nbsp;HUAZHENG CAO ,&nbsp;HAOHAN ZOU ,&nbsp;XINHENG ZHAO ,&nbsp;YAN WANG","doi":"10.1016/j.ajo.2024.12.017","DOIUrl":"10.1016/j.ajo.2024.12.017","url":null,"abstract":"<div><h3>Purpose</h3><div>To analyze the influence of individual parameters on the postoperative refractive outcomes of small incision lenticule extraction (SMILE) in myopic eyes using machine learning.</div></div><div><h3>Design</h3><div>Retrospective Clinical Cohort Study</div></div><div><h3>Methods</h3><div>This study included 477 patients (922 eyes) of SMILE and divided them into two groups based on postoperative spherical equivalent (SE) ≤ -0.50D to analyze the factors influencing postoperative refractive outcomes. The XGBoost model took 72 clinical parameters (34 biomechanical, 31 morphological, 4 surgical-related, and 3 preoperative refractive parameters) as features; randomly selected 42 eyes from the good refractive outcomes group and all eyes (a total of 42 eyes) from the poor refractive outcomes group to conduct 100 times influence factors analysis.</div></div><div><h3>Results</h3><div>The 10 most important factors influencing postoperative refractive outcomes included 3 surgery-related parameters (PTA, LTmax, and RST), 3 corneal biomechanical parameters (HC Time, Deflection Amp Max (ms), and SSI), 2 corneal morphological parameters (R Per F and Rs F), and 2 preoperative refractive parameters (SE and SD). When PTA ≥ 25.09%, LTmax ≥ 139μm, SE ≤ −7.00D, or SD ≤ −6.75D, the postoperative SE significantly increased (all P &lt; 0.05), with averages of −0.183D, −0.171D, −0.188D, and −0.184D. After controlling for age, intraocular pressure, and corneal thickness, the postoperative SE significantly increased when HC time ≥ 17.422 and Deflection Amp Max (ms) ≥ 16.616, reaching −0.209D and −0.202D.</div></div><div><h3>Conclusions</h3><div>More corneal tissue ablation, longer HC Time and Deflection Amp Max (ms), lower SSI, and higher preoperative refractive error may result in poor postoperative refractive outcomes.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"271 ","pages":"Pages 455-465"},"PeriodicalIF":4.1,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}